文献速递胸部肿瘤

LAMPAD:基于循环肿瘤DNA的整合模型预测切除后NSCLC潜在治愈

LAMPAD: An Integrated Circulating Tumor DNA-Based Model for Predicting Potential Cure in Patients With Resected NSCLC.
PubMed 文献 · J Thorac Oncol · 2026-04-17

LAMPAD是一个XGBoost-Cox模型,在术后标准landmark基础上加入术前时间点,利用两个时间点的ctDNA定量对landmark未检出MRD的I-III期NSCLC患者进行预后分层,有效区分真正无病患者,低危组2年DFS优于高危组。

要点

  • LAMPAD在landmark未检出MRD患者中分层低危与高危,2年DFS分别为97.8%与71.6%。
  • 多队列验证中低危与高危组汇总2年DFS为94.3%与72.4%。
  • 术前血检对模型贡献显著,高危患者免疫来源和肺来源cfDNA升高。

核心结论

  • LAMPAD模型优于单时间点术后ctDNA检测,能有效识别真正阴性患者,为识别潜在治愈的低危患者提供更可靠的预后工具。

研究设计与样本

  • LAMPAD为XGBoost-Cox模型,在163例I-III期NSCLC且landmark未检出MRD的患者中训练。
  • 模型纳入术前和术后两个时间点的ctDNA定量,并在多个验证NSCLC队列中评估。

主要发现

  • LAMPAD将患者分为低危组(2年DFS 97.8%)和高危组(2年DFS 71.6%),风险比0.11(95%CI 0.06-0.21,p<0.001)。
  • 在固定panel和个性化ctDNA-MRD方法的多个验证队列中表现一致,低危与高危组汇总2年DFS为94.3%与72.4%,风险比0.18(95%CI 0.13-0.25,p<0.001)。
  • SHAP分析排名前五的特征为基线ctDNA水平、TNM分期、landmark cfDNA浓度、基线cfDNA浓度和基线ctDNA状态。
  • 术前血检显著贡献于模型,甲基化分析显示高危患者免疫来源和肺来源cfDNA升高。

临床怎么用

  • 对于术后landmark未检出MRD的NSCLC患者,可结合术前ctDNA信息使用LAMPAD进一步区分低危与高危,辅助判断潜在治愈人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Evaluation of molecular residual disease (MRD) status in patients with NSCLC after surgery primarily relies on circulating tumor DNA (ctDNA) analysis. However, given the narrow postoperative window (4-6 wk) for adjuvant therapy, the approximately 70% false-negative rate of single-time point ctDNA landmark detection severely limits its utility. METHODS: Here, we introduce LAMPAD, an XGBoost-Cox model that incorporates an additional preoperative time point alongside the standard postoperative landmark. By leveraging ctDNA quantification from both time points, it refines prognostic stratification among patients with landmark undetectable MRD, specifically identifying those who are truly disease free. RESULTS: The LAMPAD model, incorporating the top five features ranked by Shapley additive explanations analysis-baseline ctDNA level, TNM stage, landmark cell-free DNA (cfDNA) concentration, baseline cfDNA concentration, and baseline ctDNA status-was trained on 163 patients with stages I to III NSCLC with landmark undetectable MRD. The model effectively stratified patients into low-risk (2-y disease-free survival [DFS]: 97.8%) and high-risk (2-y DFS: 71.6%) groups (hazard ratio = 0.11, 95% confidence interval: 0.06-0.21, p < 0.001). LAMPAD demonstrated consistent performance across both fixed-panel and personalized ctDNA-MRD approaches in multiple validation NSCLC cohorts (pooled 2-y DFS: 94.3% versus 72.4% for low- versus high-risk groups; hazard ratio = 0.18, 95% confidence interval: 0.13-0.25, p < 0.001). Preoperative blood test markedly contributed to the LAMPAD model, with methylation analysis revealing elevated immune-derived and lung-derived cfDNA in high-risk patients, suggesting systemic immune involvement in risk stratification. CONCLUSIONS: Overall, the LAMPAD model outperforms single-time point postoperative ctDNA detection by effectively discriminating true negative patients, thereby offering a more reliable prognostic tool for identifying low-risk patients with potential for cure.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang JT, Chen KZ, Gao X, et al. LAMPAD: An Integrated Circulating Tumor DNA-Based Model for Predicting Potential Cure in Patients With Resected NSCLC. J Thorac Oncol. 2026. PMID: 42002075. doi:10.1016/j.jtho.2026.103729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。